Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 27, 2004, to announce its financial results for the quarter ended September 30, 2004. The key information for investors is contained within the accompanying press release, filed as Exhibit 99(a). This filing serves as a notification of the release of these results. While the 8-K itself does not detail the specific financial figures, it directs investors to the press release for the comprehensive quarterly performance. This is a standard procedure for publicly traded companies to disseminate important financial updates in a timely manner. Investors should refer to the referenced press release for details on revenue, expenses, net income, and any other relevant operational and financial condition metrics for the period.
Key Highlights
- 1Regeneron Pharmaceuticals (REGN) announced its financial results for the quarter ended September 30, 2004.
- 2The financial results were disclosed via a press release filed as Exhibit 99(a) to the 8-K.
- 3The 8-K filing was made on October 27, 2004, with the event date of the announcement being October 26, 2004.
- 4This filing is primarily a notification of the release of quarterly financial information.
- 5Investors are directed to the press release for specific financial data and operational highlights.
- 6The information in this 8-K is not deemed 'filed' for the purposes of securities laws, except where specifically incorporated by reference.